US Pharmaceutical Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. US Pharmaceutical Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. US Pharmaceutical Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Evolution of Biologics and mRNA Technology
5.1.2 Revolution by Personalized Medicine
5.1.3 Tendency to develop Medication Used for Chronic Diseases

5.2 Market Opportunities

5.2.1 Expansion into Emerging Markets
5.2.2 Investment in Research and Development for Niche Therapies
5.2.3 Leveraging Real World Evidence

5.3 Future Trends

5.3.1 Increased Decentralized Clinical Trials
5.3.2 Pharma Sustainability Initiatives
5.3.3 Digital Therapeutics Going Big

5.4 Impact of Drivers and Restraints

6. US Pharmaceutical Market Country Analysis

6.1 US Pharmaceutical Market Overview

6.2 US Pharmaceutical Market Revenue 2020-2030 (US$ Billion)

6.3 US Pharmaceutical Market Forecast Analysis

7. US Pharmaceutical Market Analysis – by Product

7.1 Vaccines

7.1.1 Overview
7.1.2 Vaccines: US Pharmaceutical Market – Revenue and Forecast to 2031 (US$ Billion)

7.2 Biologics & Biosimilars

7.2.1 Overview
7.2.2 Biologics & Biosimilars: US Pharmaceutical Market – Revenue and Forecast to 2031 (US$ Billion)

7.3 Small Molecules

7.3.1 Overview
7.3.2 Small Molecules : US Pharmaceutical Market – Revenue and Forecast to 2031 (US$ Billion)

8. US Pharmaceutical Market – United States Analysis

8.1 United States

8.1.1 United States: US Pharmaceutical Market – Revenue and Forecast to 2030 (US$ Billion)

8.1.1.1 United States: US Pharmaceutical Market Breakdown, by Product

9. Competitive Landscape

9.1 Heat Map Analysis

9.2 Company Positioning and Concentration

10. US Pharmaceutical Market Industry Landscape

10.1 Overview

10.2 Mergers and Acquisitions

10.3 Agreements, Collaborations, and Joint Ventures

10.4 New Product Launches

10.5 Expansions and Other Strategic Developments

11. Company Profiles

11.1 Moderna Inc

11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments

11.2 AbbVie Inc

11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments

11.3 Gilead Sciences Inc

11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments

11.4 Regeneron Pharmaceuticals Inc

11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments

11.5 Merck & Co Inc

11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

11.6 Abbott Laboratories

11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments

11.7 Bristol-Myers Squibb Co

11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments

11.8 Vertex Pharmaceuticals Inc

11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments

11.9 Pfizer Inc

11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments

11.10 Eli Lilly and Co

11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

11.11 Bayer AG

11.11.1 Key Facts
11.11.2 Business Description
11.11.3 Products and Services
11.11.4 Financial Overview
11.11.5 SWOT Analysis
11.11.6 Key Developments

11.12 Johnson & Johnson

11.12.1 Key Facts
11.12.2 Business Description
11.12.3 Products and Services
11.12.4 Financial Overview
11.12.5 SWOT Analysis
11.12.6 Key Developments

11.13 Amgen Inc

11.13.1 Key Facts
11.13.2 Business Description
11.13.3 Products and Services
11.13.4 Financial Overview
11.13.5 SWOT Analysis
11.13.6 Key Developments

11.14 Takeda Pharmaceutical Co Ltd

11.14.1 Key Facts
11.14.2 Business Description
11.14.3 Products and Services
11.14.4 Financial Overview
11.14.5 SWOT Analysis
11.14.6 Key Developments

11.15 Zoetis Inc

11.15.1 Key Facts
11.15.2 Business Description
11.15.3 Products and Services
11.15.4 Financial Overview
11.15.5 SWOT Analysis
11.15.6 Key Developments

12. Appendix

12.1 About Business Market Insights